Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on Jun 13, 2020 3:15pm
89 Views
Post# 31147100

RE:RE:RE:RE:2019 Yearend Financials

RE:RE:RE:RE:2019 Yearend Financials
RPINVESTOR1 wrote: The Company definitely has no money.

I am amazed at the number of relationships that have soured because Replicel has not kept their side of the bargain.....

- Partnerships with Shiseido and now the Chinese firm.

- Stock placements in 2016 and beyond where very modestly priced stock is down over 50% and warrants were never in danger of being exercised.

- A complete lack of respect for the people who own the Company.

- Letting down the preferred shareholders who obviously are not receiving dividends in cash.

To borrow a saying from the late Economist Milton Friedman and modify it slightly - "If you put Lee Buckler in charge of the Sahara Desert, there would be a sand shortage within 10 years!"
 


Couldn't have said it better.
Bullboard Posts